OBJECTIVES: Combined pulmonary fibrosis and emphysema (CPFE) is a unique disorder that is usually diagnosed on the basis of high resolution computed tomography (HRCT) findings. It is unclear whether CPFE is an independent prognostic factor in patients with nonsmall-cell lung cancer (NSCLC). Therefore, we conducted a retrospective analysis to assess the impact of CPFE on the prognosis of patients with completely resected NSCLC.
INTRODUCTION
Combined pulmonary fibrosis and emphysema (CPFE) is a unique disorder defined by radiological findings on high resolution computed tomography (HRCT) and clinically characterized by subnormal spirometry (mild airflow limitation and mild lung volume restriction), severe impairment of gas exchange and desaturation during exercise [1] . Patients with CPFE have a significantly increased risk of lung cancer [2, 3] , and lung cancer patients without CPFE, on average, survive longer than those with CPFE [4] . However, it is unclear whether CPFE is an independent prognostic factor in patients with non-small-cell lung cancer (NSCLC). It is also unclear why patients with NSCLC and CPFE have a poor prognosis. Therefore, we conducted a retrospective analysis to evaluate the impact of CPFE on the prognosis of NSCLC patients after complete tumour resection.
METHODS

Patients
We retrospectively reviewed patients diagnosed with NSCLC who underwent surgery at the Tazuke Kofukai Medical Research Institute, Kitano Hospital between January 2007 and December 2012. All patients met the following criteria: pathological confirmation of NSCLC; no preoperative treatment; complete curative resection (wedge resections were not included); no microscopic residual tumour; no history of autoimmune disease or connective tissue disease; no evidence of active infection such as pneumonia or tuberculosis before surgery; evaluation according to a HRCT scan that was acquired at the time of diagnosis and was available for review; no history of acute exacerbation of chronic obstructive pulmonary disease or interstitial lung disease within 3 months before surgery; and availability of laboratory data and follow-up information. Two pulmonologists, who had no knowledge of any prior clinicopathological reports relevant to these cases, reviewed the HRCT findings and accordingly classified patients into four groups: those with CPFE, those with fibrosis, those with emphysema or those with a normal lung except for the presence of the tumour. Patients with CPFE met the criteria described by Cottin et al. [1] . These were (A) the presence of emphysema on a CT scan, defined as well-demarcated areas of reduced attenuation in comparison with a contiguous normal lung and delineated by a very thin (<1 mm) wall or no wall and/or multiple bullae (>1 cm) with upper zone predominance and (B) diffuse parenchymal lung disease with significant pulmonary fibrosis apparent on a CT scan, defined as reticular opacities with peripheral and basal predominance, honeycombing, architectural distortion and/or traction bronchiectasis or bronchiolectasis, possibly with associated focal groundglass opacities and/or areas of alveolar condensation, but these should not be prominent.
Only cases for which a CT scan was available for review were included. Patients with connective tissue disease at the time of CPFE diagnosis were excluded from the study, as were patients with a diagnosis of other interstitial lung diseases such as drug-induced interstitial lung disease, pneumoconiosis, hypersensitivity pneumonitis, sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis and eosinophilic pneumonia. Patients who met both criteria were classified into the CPFE group, those who met criterion A were classified into the emphysema group, those who met criterion B were classified into the fibrosis group and those who met neither of the criteria were classified into the normal lung group. Lung cancer was classified histologically according to the World Health Organization guidelines [5] , and the disease was staged according to the seventh edition of the TNM classification of malignant tumours [6] . Preoperative staging was evaluated by contrast-enhanced CT scan of chest and abdomen, contrast-enhanced MRI scan of brain and PET scan of the whole body or bone scintigraphy for all patients included into the present study. If patients could not perform MRI scans of brain, they received CT scans of brain. The study protocol was approved by the ethics committee of the Tazuke Kofukai Medical Research Institute, Kitano Hospital, and was in accordance with the guidelines outlined in the Declaration of Helsinki.
Evaluation of clinicopathological factors
The following clinical characteristics were retrieved from the available clinical records: age, sex, body mass index (BMI), Eastern Cooperative Oncology Group performance status (ECOG-PS), smoking history, spirometry results, resected side, surgical procedure, lung cancer histology, pathological stage, pathological tumour status, pathological lymph node status and cause of death. Diseasefree survival (DFS) was calculated from the date of surgery until the date of recurrence or death or until the date the patient was last known to be disease free. Overall survival (OS) was calculated from the date of surgery until the date of death from any cause or until the date on which the patient was last known to be alive.
Statistical analysis
We estimated DFS and OS using a Kaplan-Meier analysis [7] . Differences between survival curves were tested for statistical significance using the two-tailed log-rank test. We used the Bonferroni correction to account for multiple testing, and on this basis, a two-tailed P-value of <0.0125 was considered statistically significant. Univariate and multivariate prognostic analyses were performed for DFS and OS outcomes using the Cox proportional hazards model. Categorical variables were compared using the χ 2 test, and continuous variables were compared using the KruskalWallis rank-sum test. All statistical analyses were performed using the statistical software R version 2.13.1 (R Foundation for statistical computing, Vienna, Austria) and the IBM SPSS SamplePower (IBM, Tokyo, Japan). All P-values are two-sided, and those <0.05 were considered statistically significant, except for when the Bonferroni correction was applied. 
RESULTS
Patients included in this study
Data from 445 patients diagnosed with NSCLC and who underwent surgery at our hospital between January 2007 and December 2012 were obtained from the hospital's database. Eighty patients were excluded because of preoperative treatment (n = 25), incomplete resection (n = 45) or a history of connective tissue disease (n = 10). Thus, a total of 365 patients were included in this study. The clinicopathological characteristics of the four groups (CPFE, fibrosis, emphysema and normal lung) are summarized in Table 1 (Table 1) . Overall, patients with CPFE were significantly older, were more likely to be men, had a poorer ECOG-PS, were more likely to be smokers, had a lower %FEV 1 and FEV 1 /FVC, more frequently had a more advanced pathological stage, had a higher rate of squamous cell carcinoma and had a higher rate of disease recurrence than patients with a normal lung.
The prognostic significance of combined pulmonary fibrosis and emphysema A Kaplan-Meier analysis was performed to evaluate the prognosis of the four groups (Fig. 1) . The DFS was significantly shorter in the CPFE group compared with the normal lung and emphysema groups (P-values vs emphysema and normal lung groups: both <0.01, respectively) (Fig. 1A) . There was no significant difference in DFS between the CPFE and fibrosis groups (P = 0.28). The normal lung group had a significantly longer DFS than the fibrosis group (P < 0.01) and also a longer DFS than the emphysema group, although this difference was not significant (P = 0.03).
In the analyses of OS, the prognosis of the CPFE group was significantly worse than that of the normal lung and emphysema groups (P-values vs the emphysema and normal lung groups; both <0.01) (Fig. 1B) . The OS of the CPFE group was shorter than that of the fibrosis group, although this difference was not significant (P = 0.04), and the OS of the normal lung group was significantly longer than that of the fibrosis group (P < 0.01). There was no significant difference in OS between the normal lung and emphysema groups (P = 0.44).
Univariate and multivariate analyses of factors associated with the prognosis of non-small-cell lung cancer
The univariate analysis revealed nine significant risk factors for DFS: age, sex, smoking history, histology, tumour status, lymph node status, fibrosis, emphysema and CPFE ( Table 2 ). The multivariate analysis revealed that CPFE was a statistically significant, independent predictive factor for DFS (HR: 2.52; 95% CI: 1.24-5.13; P = 0.01). The other independent prognostic factors were tumour status (HR: 1.65; 95% CI: 1.03-2.64, P = 0.04) and lymph node status (HR: 3.53; 95% CI: 2.22-5.62, P < 0.01).
The univariate analysis identified nine significant risk factors for OS: age, sex, ECOG-PS, smoking history, histology, tumour status, lymph node status, fibrosis and CPFE (Table 3 ). In the multivariate analysis, CPFE was shown to be a statistically significant independent predictor of OS, (HR: 4.53; 95% CI: 1.91-10.7; P < 0.01). The other independent prognostic factors were age (HR: 2.28; 95% CI: 1.17-4.45, P = 0.02) and lymph node status (HR: 2.52; 95% CI: 1.33-4.78, P < 0.01). Eighty-one patients received postoperative adjuvant chemotherapy in this study. We evaluated the impact of CPFE on the prognosis of the 284 NSCLC patients who did not undergo adjuvant chemotherapy. Univariate analysis showed that CPFE was also a significant predictive factor among these patients for DFS (HR: 9.89; 95% CI: 4.54-21.5, P < 0.01) and OS (HR: 12.4; 95% CI: 5.16-29.9, P < 0.01), respectively.
The prognostic significance of CPFE after recurrence
We also performed a Kaplan-Meier analysis to evaluate the prognosis of the four groups after recurrence. The OS of the CPFE group was significantly shorter than that of the normal lung group (P < 0.01) and also tended to be shorter than that of the emphysema group (P = 0.18) (Fig. 2) . The characteristics of CPFE patients who experienced NSCLC recurrence are summarized in Table 4 . Three patients could not receive treatment, including chemotherapy or radiotherapy, because of worsened PS (N = 1) or worsened interstitial lung disease during adjuvant chemotherapy (N = 2). In addition, four of the seven patients had to discontinue chemotherapy because of acute exacerbation of interstitial lung disease, and one patient experienced febrile neutropaenia during chemotherapy after recurrence. Only 2 of the 10 patients with CPFE who experienced NSCLC recurrence could undergo optimal chemotherapy.
Power calculation
Alpha 0.05, beta 0.2, 5-year survival rate of the control group 91.2%, 5-year survival rate of the CPFE group 27.0%, case number rate of the control group to the CPFE group 245:20, indicates that we need at least 8 CPFE patients and 72 control patients. These results mean the sample size of the present study has enough power.
DISCUSSION
In the present study, we demonstrated that CPFE was an independent factor for a poor prognosis in NSCLC. This is the first study to show that CPFE is an independent prognostic factor for both OS and DFS in this malignancy. We also demonstrated that the OS of CPFE patients after NSCLC recurrences was significantly worse than that of patients without CPFE.
We evaluated the prognostic significance of CPFE, fibrosis, emphysema and a normal lung, and demonstrated that CPFE is a distinct phenotype associated with an extremely poor prognosis in NSCLC patients. In previous reports, emphysema was shown to be associated with lung cancer mortality [8] , and pulmonary fibrosis was also found to be associated with a poor prognosis in patients with NSCLC [9, 10] . In this study, NSCLC patients with emphysema were more likely to have a poor prognosis compared with NSCLC patients with an otherwise normal lung, and the prognosis of NSCLC patients with fibrosis was even worse, which supports the findings of previous reports. The prognostic impact of CPFE on the OS of NSCLC patients was assessed using the log-rank test in a previous study [4] . In this study, we showed that CPFE was a predictive factor for both OS and DFS using the same test. Furthermore, multivariate analysis demonstrated that CPFE was a prognostic factor for shorter DFS and OS, independent of other important factors affecting the prognosis of NSCLC patients. It remains unclear why CPFE is an independent prognostic factor for a poor outcome in NSCLC patients. However, we found that NSCLC recurred earlier and more frequently (50%) in patients with CPFE, negating the effects of postoperative adjuvant chemotherapy, which may explain the poor prognosis of these patients. The mechanism by which CPFE results in more frequent NSCLC recurrence remains unclear, although CPFE itself encompasses previously reported risk factors for lung cancer progression, including smoking, emphysema and pulmonary fibrosis [11] [12] [13] [14] .
In addition to early recurrence, the OS of NSCLC patients with CPFE after recurrences was significantly shorter than that of patients without CPFE (Fig. 2) . This might be partly due to a reduced tolerance of chemotherapy, and thus a lesser chance of them undergoing optimal treatment after recurrence. In the present study, only 2 of 10 patients with CPFE who experienced NSCLC recurrence could undergo optimal chemotherapy, and 6 of the 8 patients with CPFE after recurrence experienced acute exacerbation of interstitial lung disease. In all of these six cases, acute exacerbation occurred after the administration of The prognosis of the CPFE group was significantly worse than that of the normal lung group (P < 0.01) and tended to be worse than that of the emphysema group (P = 0.18).
chemotherapy, suggesting a causal relationship between them. Thus, the risk of exacerbation of interstitial lung disease denied patients the opportunity of optimal chemotherapy. There are three limitations to the present study. The first is its retrospective nature. The second is that it included only a relatively small number of patients with CPFE. The other limitation is that we did not evaluate the prognosis of patients with advanced NSCLC who could not be treated surgically. Prospective studies with larger patient cohorts are required to overcome these limitations.
The impact of CPFE on the prognosis of NSCLC patients shown in the present study would require us to reconsider the indication for surgery and adjuvant chemotherapy. Several underlying lung diseases need to be considered when deciding upon the appropriateness of surgery. For example, in patients with idiopathic pulmonary fibrosis (IPF), the risk of acute exacerbation after surgery is a limiting factor in surgical treatment [15] . In addition, median length of survival from time of IPF diagnosis ranges from 2.5 years to 3.5 years [16] [17] [18] . Because the patients with CPFE have emphysema in the upper lung fields and fibrosis in the lower lung fields, the normal lung volume of the patients with CPFE is so small. In some cases with CPFE, surgeons are forced to select lesser resection to spare the normal lung volume. Further studies are necessary to investigate whether conventional indications for surgery or adjuvant chemotherapy could improve the prognosis of NSCLC patients with CPFE.
In conclusion, our findings indicate that CPFE is a significant predictive factor for a poor prognosis in NSCLC. The early recurrences of this malignancy combined with a reduced tolerance to the optimal therapeutic regimen after recurrence might result in a shorter OS for patients with CPFE. Treatment strategies for these patients, including indications for surgery and chemotherapy, should be re-evaluated in clinical practice. Further studies are also necessary to confirm our findings, to elucidate the mechanism by which CPFE impacts on the clinical outcomes of NSCLC, and to develop optimal treatment strategies for NSCLC patients with CPFE. acute exacerbation of interstitial pneumonia; UIP: usual interstitial pneumonia; BSC: best supportive care; FN: febrile neutropenia.
